ANTIINFLAMMATORY EFFECTS OF JOBELYN Phase I Results

1
ANTI-INFLAMMATORY EFFECTS OF JOBELYN(Phase I
Results)

• PREPARED BY
• VIVACELL BIOTECHNOLOGY GMBH,
• Ferdinand-Porsche Str. 5,
• D 79211 Denzlingen, Germany and its
  Affiliates with
• offices at Freiburg, Germany and VivaCell,
  Córdoba, Spain
• Dr. Bernd Fiebich
• VivaCell Technologies GmbH
• AND
• Dr. Kurt Appel
• VivaCell Technologies GmbH

2
Anti-inflammatory effects of Jobelyn

• Effects of Jobelyn on lipopolysaccharide(LPS)-indu
  ced cytokine, and PGE2 release in human monocytes
• Human primary monocytes were isolated from buffy
  coats of healthy human blood donors.
• Cells were seeded in 24-well plates for ELISA
  measurements.
• Monocytes were incubated without or with LPS (10
  ng/ml) for 24 h in absence or presence of Jobelyn
  (6 doses 1, 10, 50, 100, 250, and 500 µg/ml
  depending on cytotoxicity), which were added 30
  min before LPS treatment.
• After 24 h (with or without LPS), supernatants
  were removed, centrifuged and investigated for
  cytokines (IL-1beta, TNFalpha, IL-6, IL-8), and
  PGE2 concentrations in ELISA using manufacturers
  protocol.

3
IL-8 ( of LPS control)
JOBELYN 1 µg/ml
LPS (10 ng/ml)
JOBELYN 10 µg/ml
JOBELYN 100 µg/ml
JOBELYN 250 µg/ml
JOBELYN 500 µg/ml
Figure 1 Inhibitory effects of JOBELYN on
LPS-induced release of IL-8 in primary human
monocytes (n3). Monocytes were pre-incubated
with JOBELYN in the indicated concentrations for
30 min and subsequently treated with LPS (10
ng/ml) for 24 h. IL-8 in the supernatants was
measured using an enzyme immunoassay (ELISA).
4
IL-1 ( of LPS control)
JOBELYN 1 µg/ml
LPS (10 ng/ml)
JOBELYN 10 µg/ml
JOBELYN 100 µg/ml
JOBELYN 250 µg/ml
JOBELYN 500 µg/ml
Figure 2 Inhibitory effects of JOBELYN on
LPS-induced release of IL-1beta in primary human
monocytes (n3). Monocytes were pre-incubated
with JOBELYN in the indicated concentrations for
30 min and subsequently treated with LPS (10
ng/ml) for 24 h. IL-1beta in the supernatants was
measured using an enzyme immunoassay (ELISA).
5
TNF ( of LPS control)
JOBELYN 1 µg/ml
LPS (10 ng/ml)
JOBELYN 10 µg/ml
JOBELYN 100 µg/ml
JOBELYN 250 µg/ml
JOBELYN 500 µg/ml
Figure 3 Inhibitory effects of JOBELYN on
LPS-induced release of TNFalpha in primary human
monocytes (n3). Monocytes were pre-incubated
with JOBELYN in the indicated concentrations for
30 min and subsequently treated with LPS (10
ng/ml) for 24 h. TNFalpha in the supernatants was
measured using an enzyme immunoassay (ELISA).
6
IL-6 ( of LPS control)
JOBELYN 1 µg/ml
LPS (10 ng/ml)
JOBELYN 10 µg/ml
JOBELYN 100 µg/ml
JOBELYN 250 µg/ml
JOBELYN 500 µg/ml
Figure 4 Inhibitory effects of JOBELYN on
LPS-induced release of IL-6 in primary human
monocytes (n3). Monocytes were pre-incubated
with JOBELYN in the indicated concentrations for
30 min and subsequently treated with LPS (10
ng/ml) for 24 h. IL-6 in the supernatants was
measured using an enzyme immunoassay (ELISA).
7
PGE2 ( of LPS control)
JOBELYN 1 µg/ml
LPS (10 ng/ml)
JOBELYN 10 µg/ml
JOBELYN 100 µg/ml
JOBELYN 250 µg/ml
JOBELYN 500 µg/ml
Figure 5 Inhibitory effects of JOBELYN on
LPS-induced release of PGE2 in primary human
monocytes (n2 on LPS-induced release of PGE2 in
primary human monocytes (n2). Monocytes were
pre-incubated with JOBELYN in the indicated
concentrations for 30 min and subsequently
treated with LPS (10 ng/ml) for 24 h. PGE2 in the
supernatants was measured using an enzyme
immunoassay (EIA).